Important Update: Masks required at Poche Centre
24 July 2020
In line with NSW Health advice, as of Monday 27th July all patients and carers/family members coming into The Poche Centre will be required to bring their own suitable protective mask and wear it during their consultation/procedure. Washable/material masks are sufficient providing these masks meet the basic protection specifications.
If a patient does not bring a mask, your appointment may need to be rescheduled.
All MIA direct patient care staff are also required to wear masks when treating patients and when 1.5m social distancing cannot be maintained.
We also remind visitors that no one can enter The Poche Centre if they are unwell, if they are awaiting COVID-19 test results, if they have been in close contact with a COVID-19 case or if they have visited locations listed here by NSW Health.
For further information see: AN IMPORTANT UPDATE FOR OUR PATIENTS AND VISITORS ABOUT CORONAVIRUS (COVID-19)
Your cooperation and understanding is appreciated as we work to protect the health of our patients and staff.
New research shows that patients who are more likely to respond to immunotherapy treatment have a greater diversity in their gut bacteria.
2018 will be bigger than ever, and a little bit different.
MIA's epidemiologist explains her new research on how country of residence should be considered when identifying melanoma risk.
Congratulations to our Conjoint Medical Directors, Professor Georgina Long and Professor Richard Scolyer, who have today been announced as Fellows of the Australian Academy of Health and Medical Sciences.
New research shows potentially deadly UV damage can appear decades earlier than you think.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.